Clinovation Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$23,887	51
2023	Research	$13,635	11
2021	Research	$17,702	4
2019	Research	$5,275	1

Breakdown

Who paid Research payments · program years 2019–2024

Biohaven Pharmaceutical Holding Company Ltd. $37,523 62 payments
Myovant Sciences Inc. $17,702 4 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $5,275 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 23 Doubleblind Randomized Placebocontrolled Safety and Efficacy Trial of Bhv3000 Rimegepant Orally Disintegrating Tablet Odt for the Acute Treatment of Chronic Rhinosinusitis CRS With Or Without Nasal Polyps $37,523 62 payments
An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids $13,777 3 payments
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole Opc34712 in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $5,275 1 payment
Liberty Extension: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids $3,925 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.